Windtree Therapeutics Correlations
| WINT Stock | USD 0.50 0.01 1.96% |
The current 90-days correlation between Windtree Therapeutics and Palisade Bio is 0.16 (i.e., Average diversification). The correlation of Windtree Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Windtree Therapeutics Correlation With Market
Modest diversification
The correlation between Windtree Therapeutics and DJI is 0.23 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Windtree Therapeutics and DJI in the same portfolio, assuming nothing else is changed.
Windtree |
Moving together with Windtree Stock
| 0.82 | VALN | Valneva SE ADR | PairCorr |
| 0.63 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.74 | IPSC | Century Therapeutics | PairCorr |
| 0.62 | MDWD | Mediwound | PairCorr |
| 0.62 | MTEM | Molecular Templates | PairCorr |
| 0.65 | NKTX | Nkarta Inc | PairCorr |
| 0.72 | AGL | agilon health | PairCorr |
| 0.78 | BACK | IMAC Holdings | PairCorr |
| 0.74 | CYRX | Cryoport | PairCorr |
| 0.7 | SHG | Shinhan Financial | PairCorr |
| 0.83 | EC | Ecopetrol SA ADR | PairCorr |
Moving against Windtree Stock
| 0.54 | KZR | Kezar Life Sciences | PairCorr |
| 0.51 | NXGLW | NexGel Warrant | PairCorr |
| 0.5 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.88 | T | ATT Inc Aggressive Push | PairCorr |
| 0.71 | HD | Home Depot | PairCorr |
| 0.64 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.63 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.6 | INTC | Intel Fiscal Year End 23rd of January 2025 | PairCorr |
| 0.6 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.51 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
| 0.5 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.49 | HPQ | HP Inc | PairCorr |
| 0.48 | VFS | VinFast Auto Earnings Call This Week | PairCorr |
| 0.43 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.41 | GE | GE Aerospace Fiscal Year End 28th of January 2025 | PairCorr |
| 0.33 | DD | Dupont De Nemours Fiscal Year End 4th of February 2025 | PairCorr |
| 0.32 | JPM | JPMorgan Chase Fiscal Year End 10th of January 2025 | PairCorr |
Related Correlations Analysis
| 0.65 | 0.45 | 0.84 | 0.61 | NRBO | ||
| 0.65 | 0.55 | 0.53 | 0.59 | PALI | ||
| 0.45 | 0.55 | 0.57 | 0.41 | LIXT | ||
| 0.84 | 0.53 | 0.57 | 0.41 | ATXI | ||
| 0.61 | 0.59 | 0.41 | 0.41 | CFRX | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Risk-Adjusted Indicators
There is a big difference between Windtree Stock performing well and Windtree Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Windtree Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NRBO | 3.39 | (0.84) | 0.00 | (0.23) | 0.00 | 6.76 | 25.62 | |||
| PALI | 3.52 | (0.50) | 0.00 | (1.92) | 0.00 | 5.97 | 24.25 | |||
| LIXT | 4.59 | 0.26 | 0.01 | (0.24) | 5.79 | 7.95 | 70.38 | |||
| ATXI | 3.33 | (0.54) | 0.00 | (0.51) | 0.00 | 6.81 | 23.22 | |||
| CFRX | 5.26 | (0.40) | 0.00 | (0.25) | 0.00 | 12.23 | 55.69 |
Windtree Therapeutics Corporate Executives
Elected by the shareholders, the Windtree Therapeutics' board of directors comprises two types of representatives: Windtree Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Windtree. The board's role is to monitor Windtree Therapeutics' management team and ensure that shareholders' interests are well served. Windtree Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Windtree Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.